These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1970 related articles for article (PubMed ID: 11714897)

  • 21. Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro.
    Montesano R; Kumar S; Orci L; Pepper MS
    Lab Invest; 1996 Aug; 75(2):249-62. PubMed ID: 8765325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.
    Tian X; Song S; Wu J; Meng L; Dong Z; Shou C
    Biochem Biophys Res Commun; 2001 Aug; 286(3):505-12. PubMed ID: 11511087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins.
    Gingras D; Lamy S; Béliveau R
    Biochem J; 2000 Jun; 348 Pt 2(Pt 2):273-80. PubMed ID: 10816419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
    Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
    EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
    Gerber HP; Malik AK; Solar GP; Sherman D; Liang XH; Meng G; Hong K; Marsters JC; Ferrara N
    Nature; 2002 Jun; 417(6892):954-8. PubMed ID: 12087404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells.
    Cheng T; Cao W; Wen R; Steinberg RH; LaVail MM
    Invest Ophthalmol Vis Sci; 1998 Mar; 39(3):581-91. PubMed ID: 9501870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor.
    Graeven U; Rodeck U; Karpinski S; Jost M; Philippou S; Schmiegel W
    Cancer Res; 2001 Oct; 61(19):7282-90. PubMed ID: 11585767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells.
    Nakamura S; Murakami-Mori K; Rao N; Weich HA; Rajeev B
    J Immunol; 1997 May; 158(10):4992-5001. PubMed ID: 9144519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor and the regulation of angiogenesis.
    Ferrara N
    Recent Prog Horm Res; 2000; 55():15-35; discussion 35-6. PubMed ID: 11036931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor.
    Mandriota SJ; Pepper MS
    J Cell Sci; 1997 Sep; 110 ( Pt 18)():2293-302. PubMed ID: 9378778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The adapter protein, Grb10, is a positive regulator of vascular endothelial growth factor signaling.
    Giorgetti-Peraldi S; Murdaca J; Mas JC; Van Obberghen E
    Oncogene; 2001 Jul; 20(30):3959-68. PubMed ID: 11494124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 99.